Loading organizations...

§ Private Profile · South San Francisco, CA, USA
Star Therapeutics is a technology company.
We transform the lives of patients with serious diseases by discovering and developing best-in-class antibody therapies.
Star Therapeutics has raised $320.0M across 3 funding rounds.
Star Therapeutics has raised $320.0M in total across 3 funding rounds.
Star Therapeutics has raised $320.0M across 3 funding rounds. Most recently, it raised $130.0M Series D in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $130M Series D | Sanofi Ventures, Maneka Mirchandaney | Foresite Capital, OrbiMed, Sofinnova Investments, Westlake Village BioPartners, Frazier Life Sciences, Craig Gordon, Janus Henderson Investors | Announced |
| Sep 1, 2023 | $90M Series C | Sofinnova Investments | Foresite Capital, OrbiMed, Sanofi Ventures, Versant Ventures, Westlake Village BioPartners, Agent Capital, Catalio Capital, Cormorant Asset Management, Cowen Healthcare Investments, Vijay Lathi, Nybc Ventures, Qatar Investment Authority, Matthew Hammond, Amrit Nagpal, Soleus Capital | Announced |
| Feb 16, 2022 | $100M Venture Round | — | Vijay Lathi, Amrit Nagpal, Beth Seidenberg, Cormorant Asset Management, Cowen Healthcare Investments, Carl Gordon, RA Capital Management | Announced |
Star Therapeutics is a clinical-stage biotechnology company developing best-in-class antibody therapies for rare diseases, particularly bleeding disorders like von Willebrand disease (VWD).[1][2][4][5] Its lead product, VGA039, is a first-in-class monoclonal antibody targeting Protein S to restore blood clotting balance, serving patients with VWD and other hemostatic disorders through a universal therapy approach; the company has initiated a pivotal Phase 3 trial with monthly subcutaneous dosing and reported positive interim Phase 1 data in December 2024.[1][5][6] Star's pipeline-in-a-product strategy identifies shared biology across multiple rare diseases to enable single therapies, addressing unmet needs for millions lacking effective treatments; backed by over $300 million in funding, it shows strong growth momentum with an oversubscribed $125 million Series D in early 2025.[3][5][6]
Founded in 2018 by Adam Rosenthal, Ph.D., in South San Francisco, California, Star Therapeutics emerged from stealth in February 2022 after raising over $100 million from investors like Westlake Village BioPartners, OrbiMed, and RA Capital.[1][3][5] Rosenthal, with deep expertise in antibody development—including inventing four first-in-class antibodies like the approved ENJAYMO for cold agglutinin disease—launched Star to tackle the 7,000 rare diseases with only ~650 FDA-approved drugs.[3][5] The idea stemmed from applying rare disease and antibody discovery expertise to target shared biology across diseases; early traction included spinning out Electra Therapeutics with a Phase 1 program, evolving into a focused hematology pipeline led by VGA039.[3]
Star rides the wave of precision antibody therapies in rare hematology, targeting VWD—a common inherited bleeding disorder affecting >50,000 U.S. patients—amid rising demand for hemostatic innovations beyond plasma-derived concentrates like Wilate or Voncento.[1][5][6] Timing aligns with post-pandemic biotech resurgence and investor appetite for de-risked clinical assets, as Phase 3 data could disrupt a market long dominated by legacy treatments from Shire and others.[1] Favorable forces include novel biology interrogation in underserved rare diseases and subcutaneous delivery advantages; Star influences the ecosystem by validating multi-disease antibody platforms, potentially inspiring similar "one-drug-many-indications" models in immunology.[2][3][4]
Star Therapeutics is poised for Phase 3 readout of VGA039 in VWD by late 2026-2027, with Series D funds extending runway for expansion into additional bleeding disorders and pipeline growth.[5][6] Trends like AI-driven biology discovery and hemostatic therapy demand will accelerate its path, potentially yielding a first universal clotting therapy and blockbuster status. Its influence may evolve from rare disease innovator to hematology leader, transforming patient lives through shared-biology breakthroughs that began with Rosenthal's vision of one therapy for many unmet needs.[3][5]
Star Therapeutics has raised $320.0M in total across 3 funding rounds.
Star Therapeutics's investors include Sanofi Ventures, Maneka Mirchandaney, Foresite Capital, OrbiMed, Sofinnova Investments, Westlake Village BioPartners, Frazier Life Sciences, Craig Gordon, Janus Henderson Investors, Versant Ventures, Agent Capital, Catalio Capital Management.